Enanta reports FY2024 revenue $67.6M, net loss $116M; RSV & immunology pipelines advance

ENANTA PHARMACEUTICALS INC

2024-FY EPS reported -$5.48 revenue$67,635,000

Q4 revenue $14.6M (down 23% YoY); full-year $67.6M vs $79.2M due to lower MAVYRET royalties.
Net loss Q4 $28.8M ($1.36/shr); full-year $116.0M ($5.48/shr) vs $133.8M prior year.
Cash & securities $248.2M at Sept 30, 2024; runway expected into fiscal 2027.
RSVPEDs zelicapavir Phase 2 topline data due December 2024; EDP-323 Phase 2a met endpoints (p<0.0001).
Immunology expansion: KIT inhibitor EPS-1421 nominated; new STAT6 discovery program initiated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.